Premium
Life‐threatening adverse reaction followed by thrombocytopenia after passive transfusion of fresh frozen plasma containing anti‐CD36 (Nak a ) isoantibody
Author(s) -
Morishita Katsuya,
Wakamoto Shinobu,
Miyazaki Toru,
Sato Shinichiro,
Fujihara Mitsuhiro,
Kaneko Sadao,
Yasuda Hiroshi,
Yamamoto Sadamitsu,
Azuma Hiroshi,
Kato Toshiaki,
Ikeda Hisami
Publication year - 2005
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2005.04320.x
Subject(s) - medicine , fresh frozen plasma , adverse effect , blood transfusion , nausea , platelet transfusion , surgery , packed red blood cells , platelet , anesthesia , refractory (planetary science) , apheresis , physics , astrobiology
BACKGROUND: Anti‐CD36 isoantibody in blood recipients is reported to cause refractoriness to platelet (PLT) transfusions and posttransfusion purpura–like syndrome. There are few reports, however, about the effects of passively transfused blood products containing this isoantibody on recipients. CASE REPORT: A 67‐year‐old Japanese woman underwent brain surgery. On the 6th postoperative day, the patient experienced tightness of the chest and nausea after receiving a transfusion of fresh frozen plasma (FFP). When she manifested hypotension, the transfusion was discontinued. No cutaneous manifestation was observed. The patient's condition gradually improved soon after the administration of steroids. RESULTS: Her pretransfusion PLT count was 17.1 × 10 4 per µL. It decreased to 1.9 × 10 4 per µL 12 hours after transfusion and recovered to 15.4 × 10 4 per µL 8 days after transfusion. The donor of the FFP had a Type I CD36 deficiency. Flow cytometric analysis identified anti‐CD36 isoantibody in the FFP. The cross‐match between the patient's PLTs and the FFP was positive. The FFP induced the aggregation of PLTs derived from healthy adults. CONCLUSION: This is the first reported case of life‐threatening adverse effects and thrombocytopenia caused by passively transfused anti‐CD36 isoantibody. The possibility of passive infusion of this antibody should be considered in the evaluation of life‐threatening transfusion reactions followed by thrombocytopenia.